Fewer than 10% of individuals that would benefit from obesity jabs like Wegovy are able to get them, caution the WHO as it releases its first advice on the therapies.
Considering in excess of 1,000,000,000 people worldwide now obese, it is advocating for more widespread and fairer availability to these injectable treatments.
Per forecasts, more than two billion are projected to be living with obesity by 2030 if no action is taken.
"The new guidance affirms that obesity is a lifelong illness that can be managed with thorough and lifelong treatment," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and distribution challenges are key obstacles to broad availability to the jabs that can aid individuals in losing substantial body mass, explains the organization.
Skinny Jab Shortage
Despite the present best projected outlook, the supply of such drugs might only reach approximately 100 million people – less than 10% of eligible patients, per the health organization.
The recommendation urges governments and firms to increase access, via measures like voluntary licensing.
Exclusive production rights on a key compound – the main ingredient of a leading brand – is due to expire in several countries in 2026.
The Way Obesity Drugs Operate
These medications mimick a body's own hormone to reduce digestion speed, curb appetite and enhance the sense of being full so people eat less.
Individuals commonly begin shedding pounds within a few weeks of beginning the once-weekly jabs.
Research indicates people may regain a significant portion a year later of stopping the drug, when their normal hunger come back.
Being carrying excess weight elevates your likelihood for developing health problems, like diabetes, heart disease, stroke, and specific malignancies.
Excess weight concerns individuals in all nations and was associated with 3.7 million deaths worldwide in 2024, as per the WHO.
